protein binding on the pharmacokinetics of sufentanil are of importance as has been pointed out previously. 3 -5 Contradictory findings for protein binding for hydromorphone in humans have been published previously. 6 -8 Effects of protein binding on the pharmacokinetics of hydromorphone might partly explain the large interindividual variability in the drug concentrations after hydromorphone administration. 9 -11 Previous literature demonstrates that factors affecting protein binding may cause changes in unbound drug concentrations. 3 4 9 Such changes may be expected to be clinically significant for drugs that are used i.v., are heavily bound to the plasma proteins, and which have a high hepatic extraction ratio. 4 5 Several opioid analgesics, such as fentanyl and sufentanil, belong to this group, 1 2 12 and significant changes in unbound opioid concentrations have been reported during perioperative pain therapy. 13 14 However, the effect of intensive care on the pharmacokinetic properties of opioids used in postoperative pain therapy is not thoroughly studied. We studied the pharmacokinetics and pharmacodynamics of sufentanil and hydromorphone during postoperative pain therapy in the intensive care unit (ICU) after cardiac surgery. During this study, we also gathered data to investigate the effect of intensive care treatment on the protein binding of sufentanil and hydromorphone as judged by the ratio between free and total plasma concentrations. We evaluated the importance of several biomarkers and biometric parameters on the protein binding during the intensive care treatment using multivariate regression analysis and hypothesized that patient characteristics and changes in physiological variables could be linked to the changes in protein binding of sufentanil and hydromorphone during intensive care pain therapy.
Methods
The study was performed in accordance with the guidelines for Good Clinical Practice and Ethical Principles for Medical Research Involving Human Subjects outlined in the Declaration of Helsinki, and adopted in October 2000 by the World Medical Association. The study was approved by the Institutional Review Board (Ethikkommission der Medizinischen Fakultät der Friedrich-AlexanderUniversität Erlangen-Nürnberg, Erlangen, Germany) and it was registered to the EudraCT (Number: 2011-003648-31) and ClinicalTrials.gov (Identifier: NCT01490268) databases. CONSORT guidelines 15 were followed and the study was clinically monitored by the Center for Clinical Studies (CCS) Erlangen.
Clinical protocol
This is a secondary analysis of a previously published study. 16 After receiving written informed consent, 50 adult patients undergoing cardiac surgery involving thoracotomy were enrolled. Inclusion and exclusion criteria are stated in the ClinicalTrials.gov-database registration and have been published recently. 16 The study was of prospective, single-blinded, randomized, single-centre design with two parallel arms and was conducted in the University Hospital of Erlangen, Germany.
Details of the clinical study protocol, drug dosing, and data management are described previously in detail. 16 Shortly, after a premedication with 7. . Sufentanil was administered as TCI using the pharmacokinetic model of Gepts and colleagues. 18 The patients were randomized into two treatment groups with target sufentanil plasma concentrations of 0.4 (Group 1) or 0.8 ng ml 21 (Group 2).
These target concentrations were kept constant throughout the anaesthesia after induction of anaesthesia. After the end of the surgery, the patients were transferred to the ICU where the sufentanil infusion was discontinued while the propofol infusion was continued for a further 2 -3 h until weaning from mechanical ventilation with an infusion rate of 2. 
Hydromorphone dosing
Throughout the study period on the ICU, hydromorphone (Palladon w inject, Mundipharma GmbH, Limburg, Germany, consisting of hydromorphone-HCl, 1 mg corresponding to 0.89 mg hydromorphone free base) was administered using three different dosing regimens: TCI, TCI as patient-controlled analgesia (TCI-PCA), and patient-controlled analgesia (PCA) as described previously in detail. 16 
Haemodynamic monitoring and vasoactive therapy
During the three study-phases, the patients were treated and monitored on the ICU according to normal ICU protocols. Arterial pressure, oxygen saturation, and heart rate were measured continuously (Siemens SL 9000 XL Patient Monitor, Siemens Medical Systems, Solna, Sweden). Parameter values were stored to the electronical database.
Vasoactive drugs were infused goal-directed depending on clinical demand to maintain mean arterial pressure of 70-90 mm Hg. Dobutamine, norepinephrine, and glycerylnitrate infusions were routinely used. If the vasoactive control was insufficient, epinephrine was administered instead of dobutamine. Laboratory data were determined regularly by blood gas analysis (ABL800 FLEX analyzer, Radiometer Medical ApS, Brønshøj, Denmark) and the results were collected from the ICU documents.
Blood sampling and concentration analysis
Arterial blood samples (4-7 ml each) were drawn. The sampling scheme has been previously described in detail. 16 The samples were kept on ice and plasma was separated within 15 min and stored at 708C until analysis. Sufentanil and hydromorphone plasma concentrations were determined using validated liquid chromatography-tandem mass spectrometric methods, as described previously. 19 20 The lower limit of quan- During explorative data analysis, data were evaluated for normality of distribution using quantile -quantile plots and Shapiro-Wilk's W-test. Since biological variables are typically positive, right skewed, and log-normally distributed, non-normal data were log-transformed before analysis but reported as non-transformed results. The data were tested for differences between the two sufentanil target groups using the unpaired t-test or the Mann -Whitney U-test. Principal component analysis was conducted to reduce multiple colinearity and to find the smallest number of linear orthogonal combinations of variables to explain the maximum amount of variability in the data. Data were scaled and normalized before principal component analysis. We selected those variables significantly associated with the principal components with highest eigenvalues.
Non-linear mixed effects modelling
Multivariate regression analysis was first applied to model free fraction, but as linear models have inherent problems such as being non-physiological and producing negative values, we used non-linear mixed effects modelling to further evaluate the effect of intensive care on protein binding. A model for free fraction as a function of selected variables identified by principal component analysis was determined using NONMEM (Version 7.2, ICON Development Solutions, Ellicot City, MD, USA). The first-order conditional estimation method with interaction was used throughout the analysis. Interindividual variability was assumed to follow a log-normal distribution: u i = u POP × e h i where u i is the individual value of the parameter u in the ith individual, u POP the population value of this parameter, and h i a random variable with the mean zero and variance v 2 h . For the intraindividual variability describing the residual errors, an additive error model was used: Y ij ¼fp ij +1 ij in which Y ij is the jth measured value of the ith individual, fp ij the corresponding predicted function value, and 1 ij is a random variable with the mean zero and variance s 2 . Models were compared by the likelihood test using the difference in the NONMEM objective function value at a significance level of P,0.05.
Goodness of fit was assessed by visual inspection of the following plots: measured values vs population (PRED) and individual predictions (IPRED), conditional weighted residuals (CWRES) vs
PRED and CWRES vs time. We further calculated the prediction error (PE ij ) and the absolute prediction error (APE ij ) to evaluate the goodness of fit: 
Results
We recruited 50 patients of which one was excluded during the anaesthesia based on the exclusion criteria, because the operation was prolonged unexpectedly. From the 49 patients (age range 40-79 yr, 36 males and 13 females), 26 and 23 patients received intraoperatively a TCI of sufentanil with target concentrations of 0.4 and 0.8 ng ml 21 , respectively.
The operation took on the median 4.7 (3.2-7.4) h, and the patients were intubated for 8. on ICU was 22.1 (4.4 -119) h. Infusion times of sufentanil and hydromorphone were similar between the groups, but according to the study protocol, the two sufentanil groups differed with respect to the total sufentanil dose and also with respect to the hydromorphone dose in the TCI phase, as predefined hydromorphone target concentrations were used in this phase (Table 1) . Total hydromorphone concentration measurements were obtained for all 49 patients, total sufentanil for 47, and free sufentanil and hydromorphone concentrations for 35 and 44 patients, respectively. Descriptive statistics (Table 1) are reported for those 35 patients for whom free and total sufentanil and hydromorphone concentrations were available. Before analysing the data, we excluded from the data set those concentration measurements that were either above the upper or below the LLQ of the assay used for drug concentration measurement (nine samples) or had unclear information regarding the sampling time (two samples). All observed individual sufentanil and hydromorphone plasma drug concentrations vs time are shown in Figure 1 . During the study period, the median protein binding of sufentanil and hydromorphone was 88.4% (IQ range 85.7 -90.5%) and 11.6% (IQ range 9.5 -14.3%), respectively. We observed a statistically significant difference (P,0.001) in sufentanil free fraction between the two sufentanil target concentration groups (Fig. 2) . The median free fraction of sufentanil was 0.13 (IQ range 0.10-0.15) in the low and 0.11 (IQ range 0.09-0.12) in the high sufentanil target concentration group. There was a trend for higher fraction of unbound sufentanil at the end of the study period, whereas hydromorphone free fraction remained essentially constant (Fig. 1) . For sufentanil, the free fraction increased at low concentrations, whereas the free fraction of hydromorphone slightly decreased at low concentrations (Fig. 3) . Table 2 summarizes the covariate data from the patients. Patients were transferred to the ICU normothermic, but we observed changes in the temperature during the first 2 h afteroperation. Four patients had fever, which was treated with acetaminophen. All patients but one were considerably overbalanced and this was reflected also by the haemoglobin and haematocrit values. The patients were hypoalbuminaemic; likewise total protein concentrations were low during the whole study period. There were slight disturbances in the acid-base homeostasis, as judged by the lactate and pH values, but these were corrected during the intensive care treatment. All patients received dobutamine. Norepinephrine and glycerylnitrate were administered to 25 and 20 patients, respectively. Epinephrine was needed for haemodynamic control in one patient. The mean (SD) arterial pressure and heart rate were 77.7 (10.7) mm Hg and 88 (12) beats min 21 , respectively, and they showed no significant changes during the study period. Among the analysed covariates (Table 2) , the following variables were identified by the principal component analysis as uncorrelated candidates for further analysis: total concentration of hydromorphone or sufentanil (ng ml 21 Figure 4 shows the time course of selected covariates. The subsequent multivariate regression analysis further indicated that the variables assumed to explain hydromorphone free fraction had only negligible to weak effect to the protein binding. The effect of intensive care on sufentanil protein binding was greater, as the variables explained 41% of the variance (r 2 ¼0.41, P,0.001).
As linear models have inherent problems such as being non-physiological and producing negative values, we used non-linear mixed effects modelling to further evaluate the effect of intensive care on sufentanil protein binding. The effects of total sufentanil concentration and volume balance were found significant on sufentanil protein binding, and incorporating the effect of BMI and lean body mass further improved the model. After testing and comparing different models, the following non-linear relationship was identified as the model which best described the free fraction of sufentanil:
where BMI is body mass index in kg m 22 , LBM the lean body mass in kg, C total the total sufentanil concentration in ng ml 21 , and V balance the volume balance in litres. LBM was estimated using the James 22 equation.
The model parameters u i were estimated with a reasonable precision ( Table 3 ). The PEs were small for both individual and population predictions (MDPE 20.7% and 0.4%, MDAPE 9.4% and 14.8%, respectively), and the CWRES were randomly and homogenously distributed (Fig. 5) . The median and 95% confidence intervals of the parameter estimates are presented in Table 3 , showing a good agreement between the population and the bootstrap parameters. Figure 6 illustrates for a typical patient of this population (LBM¼59 kg, BMI¼28 kg m 22 ) and for different values of volume balance the predicted free fraction of sufentanil as obtained by the final model.
Discussion
The large interindividual variability associated with opioid response remains a concern in clinical practice. Plasma protein binding can have clinically significant effects on the pharmacokinetics and pharmacodynamics of a drug. 11 23 Literature regarding the influence of drug binding to plasma proteins on pharmacokinetics and pharmacodynamic parameters is nevertheless scarce, 11 and the goal of this study was to evaluate the effect of postoperative intensive care on the protein binding of two opioid analgesics, sufentanil and hydromorphone, as judged by the ratio between free and total on the other hand, was highly protein bound in our study population, comparable with the previous reports. 1 2 The free fraction of sufentanil showed some variation which could be adequately assessed by a non-linear mixed-effects model with total concentration and volume balance as main Influence of intensive care treatment variables, and lean body mass and BMI as additional covariates. Previous studies have demonstrated that clinically significant changes in protein binding can occur, when an i.v. administered high extraction drug with high protein binding is used and when physiological parameters affecting protein binding are changing. 10 11 23 Whereas variations in sufentanil binding could be attributed to intensive care therapy, our results suggest that the changes in hydromorphone binding either are negligible, since protein binding as judged from free fraction remained constant during the study period. Several factors are known to affect the protein binding of drugs. 9 23 24 Although we collected all the covariates, which were at our disposal, our list is by no means exhaustive and there might still be some additional factors that could improve the results of our analysis. An important limitation of the presented model for the free fraction of sufentanil is that it is valid only in the investigated concentration range of about 0.01 to 1 ng ml 21 . For lower concentrations, the free fraction increases towards implausible high values (.0.25) and for higher concentrations, it decreases to very small values (,0.05). Intuitively, one would expect a constant unbound fraction at low sufentanil concentrations and an increasing free fraction at higher concentrations, but our data clearly show a decrease in free fraction with higher sufentanil concentrations (Fig. 3) . Accordingly, the free fraction was significantly smaller in the group with the higher sufentanil target concentration (Fig. 2) . Recently published literature demonstrates that changes in protein binding and unbound concentrations are common in critically ill patients. 5 25 Furthermore, several drugs have different free fraction depending on the total drug concentration and other factors. 26 In cardiac patients, many simultaneous physiological actions such as systemic inflammatory reaction, hypervolaemia, hypoproteinaemia, and vascular permeability are constantly changing and affecting drug pharmacokinetics during the cardiopulmonary bypass, 27 and during the initial phase of the ICU treatment. 24 Our results show that volume balance acts as one surrogate marker for these changes, but we want to emphasize that our results are observatory and further studies are warranted to fully elucidate the factors and mechanisms contributing to the protein binding during intensive care treatment. Nonetheless, a low-dose opioid analgesia is currently mostly used in cardiac anaesthesiology, which makes our findings also clinically relevant. Low serum albumin levels are very common in critically ill patients and previous reports estimate incidences for hypoalbuminaemia as high as 40 -50%. 28 29 Our results show that all patients in our study had notable hypoalbuminaemia and hypoproteinaemia during the ICU stay. This is most probably due to the cardiopulmonary bypass. It has been demonstrated that although the free concentrations of sufentanil change upon variations in serum albumin concentrations, they might correlate better with a1-acid glycoprotein plasma concentration. 1 However, the relative contribution of albumin and a1-acid glycoprotein on sufentanil and hydromorphone binding is currently unclear. Our analysis showed that sufentanil binding was not affected by the total protein or albumin levels. Similarly, hydromorphone levels were not affected by the changes in either of these parameters. Unfortunately, we did not measure a1-acid-glycoprotein levels, which might have given more information. Previously, the effect of pH has been shown to cause a 43% change in protein binding of sufentanil at the pH range of 6.728.0. 9 Most of the pH values measured after operation in our patient population were on the normal range of our laboratory, and extreme high or low values were not encountered. Interestingly, plasma lactate concentrations could explain the variance in free sufentanil fraction significantly, but the effect was small. The significant effect of volume balance may act as a surrogate for the effects of low protein concentrations, changes in the acid-base homeostasis. and also in the organ perfusion. Previous literature shows that volume overload increases mortality 30 and has profound effects on overall physiology. Thus, more patient-oriented goal-directed fluid therapy has been advocated. Sufentanil concentrations were measured mainly during elimination phase of the drug, which undoubtedly affects our results. Although sufentanil was not administered after operation, its plasma concentrations were above the minimum therapeutic level of 0.2 ng ml 21 during the early postoperative period. 35 Therefore, the changes in the protein binding may have clinical significance by affecting sufentanil pharmacokinetics and pharmacodynamics and its interactions with other analgesics dosed during intensive care. Sufentanil is currently rarely used in postoperative pain therapy due to its pharmacokinetic properties, whereas it is very useful in intraoperative care. Recent studies reporting postoperative pain therapy with sufentanil PCA further emphasize the clinical impact of our results. 36 37 It should be noted that our patient population mainly consisted of elective CABG patients and more significant changes may be attributed to sufentanil, when patients with more severe organ dysfunction are treated.
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In conclusion, sufentanil binding was significantly dependent on changes in the total drug concentration and volume balance addressing the importance of adequate dosing and fluid-guided therapy. Hydromorphone protein binding was nearly constant throughout the study period and no significant covariate effects were found.
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